Recombinant Lysostaphin Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a lyophilized glycyl-glycine endopeptidase (EC 3.4.24.75) supplied as a white to off-white cake for further processing by licensed veterinary pharmaceutical manufacturers. The enzyme cleaves the pentaglycine interpeptide bridge of staphylococcal peptidoglycan, leading to selective osmotic lysis of Staphylococcus aureus and related coagulase-negative staphylococci. As a protein with a molecular mass near 27 kDa, the active ingredient is temperature-, pH-, and moisture-sensitive; formulation into solid oral presentations and sterile liquid presentations therefore requires process controls that differ from those used for small-molecule antimicrobial agents.

The API is produced by recombinant expression in Escherichia coli, followed by chromatographic purification, endotoxin reduction, and freeze-drying. The veterinary-grade designation indicates release against supplier acceptance criteria for identity, purity, activity, bacterial endotoxins, host-cell protein, host-cell DNA, residual moisture, and microbial limits, using pharmacopoeial general methods where applicable. No compendial monograph currently exists for lysostaphin in the principal pharmacopoeias; therefore, the release profile is anchored to general chapters such as Ph. Eur. 2.6.14 for bacterial endotoxins, USP <921> for water content, and USP <61>/<62> for microbial examination of non-sterile materials.

The product is not intended for direct administration as a finished veterinary medicine. It is a processing intermediate that must be formulated, validated, and released according to the relevant VICH GL3 stability guidance and VICH GL1/GL2 analytical validation principles in the target jurisdiction. Finished-product categories may include oral powders, granules, premixes, tablets, capsules, injectable solutions, and topical or intramammary solutions. In each case, the formulator controls ionic strength, excipient compatibility, residual moisture, and terminal sterilization or aseptic processing so that enzyme activity remains within validated specification limits through the end of the labelled shelf life.

What distinguishes recombinant lysostaphin from native staphylococcal lysostaphin in veterinary API sourcing?

Native lysostaphin is purified from Staphylococcus simulans culture supernatant, which carries residual risk of staphylococcal nucleic acids, cell-wall fragments, and extracellular proteins even after chromatographic purification. Recombinant lysostaphin expressed in Escherichia coli removes staphylococcal fermentation as a contamination source and can be produced as a tag-free mature sequence. The amino acid sequence of the mature catalytic domain is generally conserved, but process-related impurities are not equivalent.

Interchangeability is governed by residual impurity profiles, not only by enzymatic activity. A native product may contain trace staphylococcal enterotoxins, lipoteichoic acid, and staphylococcal DNA; a recombinant product must instead be tested for E. coli host-cell protein and residual DNA. For example, a representative veterinary release panel may set host-cell protein below 500 ppm by ELISA, residual host-cell DNA below 100 pg/mg by quantitative PCR, and bacterial endotoxins below 0.5 EU/mg by Limulus amebocyte lysate testing. These thresholds are vendor-specific and must be justified by batch data and by the intended route of administration.

Specific activity is another point of comparison. Native preparations may contain inactive fragments or partially cleaved forms that reduce enzymatic efficiency, whereas recombinant purification can concentrate the intact catalytic domain. Suppliers usually express activity in units per milligram of protein; however, the unit definition is not harmonized across vendors. Veterinary manufacturers should therefore compare products using the same substrate strain, buffer, pH, temperature, and reaction time rather than relying on the printed unit value alone.

As with other proteinaceous APIs, repeated parenteral administration in veterinary species may elicit anti-drug antibodies that can reduce efficacy or cause hypersensitivity. The immunogenic risk is not unique to recombinant lysostaphin, but suppliers should provide host-cell protein and aggregate data because aggregates are more immunogenic than monomers. Immunogenicity testing in target species should follow relevant VICH guidance for biologicals when the product is intended for chronic use.

A supplier-defined release profile built from pharmacopoeial general chapters and VICH quality expectations may include the following tests. Because no compendial monograph exists, each batch should be reviewed against the specific certificate of analysis and the manufacturer’s validated methods.

The activity unit should be read with the exact assay conditions. A common definition states that one unit is the amount of enzyme that produces a 50% reduction in turbidity of a standardized Staphylococcus aureus suspension at 37°C in 10 min in 0.05 M phosphate buffer, pH 7.5. If a supplier uses a chromogenic or fluorogenic substrate instead of the turbidometric method, the numerical activity value may not be directly comparable. The finished-product manufacturer should request the supplier’s activity method standard operating procedure and cross-validate it against the intended formulation matrix before setting input targets.

Residual moisture is operationally important because lyophilized lysostaphin is often protected by amorphous stabilizers such as trehalose or mannitol. If the water content rises above the release limit, the glass transition temperature of the cake may fall, leading to cake shrinkage, collapse, or activity loss during storage. Karl Fischer titration by USP <921> Method Ia or Ph. Eur. 2.5.12 is recommended for API receiving inspection.

Solid-dosage processing boundaries and premix carrier requirements

Solid veterinary dosage forms containing lysostaphin are generally produced by dry blending and dry granulation because aqueous granulation exposes the enzyme to moisture and elevated drying temperatures that can reduce activity. Direct compression is feasible only when the API loading is low enough to achieve acceptable content uniformity with a pre-mixed excipient system. For higher API loadings, a roller compactor with 100 mm diameter rolls, 2–4 mm roll gap, and roll pressure below 40 bar is a representative setup for producing granules with acceptable hardness while limiting frictional heat. These parameters are not universal and require confirmation by post-compaction activity assay.

The blend should be prepared at 20–25°C and ≤40% relative humidity. Excipients such as microcrystalline cellulose, lactose monohydrate, and anhydrous dibasic calcium phosphate may be used, but the formulator should avoid strongly oxidizing agents, proteolytic enzymes, and prolonged exposure to pH below 4.0 or above 9.0. Mannitol and trehalose are frequently selected as stabilizers because they form a glassy matrix around the protein during formulation, but their compaction behavior must be evaluated by blend uniformity and tablet hardness testing on an instrumented tablet press.

Batch-to-batch activity retention in dry granulation is often controlled by excipient moisture content. When excipient water content rises above 3.0%, localized clumping in the roller compactor may reduce die-fill consistency and produce granules with wider particle-size distribution. Pre-drying of excipients at 40–50°C to a water content below 2.0% is therefore recommended before final blending.

Premix presentations for medicated feed require a carrier that provides both dilution and protection. Ground rice hulls or corn cob granules may segregate from fine enzyme powder due to particle-size differences. The premix should be manufactured with a geometric dilution sequence and screened through a 0.6 mm or 0.8 mm sieve before final blending in a double-cone or ribbon blender. Homogeneity can be assessed by taking thief samples from the blender and measuring activity, with acceptance criteria such as a relative standard deviation below 5% across sampling points.

Capsule filling on a dosator-type machine may generate localized heat and mechanical shear. When fill weight is low, activity retention should be examined after runs at 10,000–20,000 capsules/h; if activity falls below the validated limit, the manufacturer should reduce machine speed, add external cooling, or switch to a tamping-pin system.

When sterile injectable and solution presentations require low-shear aseptic handling

For injections and solutions, the lyophilized API is reconstituted in 0.9% sodium chloride or 0.05 M phosphate-buffered saline at pH 7.2–7.5. The reconstitution volume should keep the enzyme concentration above the surface-denaturation threshold, typically above 0.1 mg/mL, because dilute enzyme solutions can lose activity through adsorption to glass and plastic surfaces. The solution should be filtered through a low-protein-binding membrane such as polyethersulfone with a pore size of 0.22 µm; nylon membranes are avoided because they can bind proteins. Bioburden before sterilizing-grade filtration should be below 10 CFU/100 mL when controlled according to Ph. Eur. 2.6.12.

Aseptic processing of lysostaphin solutions requires control of pH, ionic strength, and shear. Agitation in stainless-steel mixing vessels should be limited to low-shear impellers, such as magnetic stirrers or marine-type impellers below 200 rpm, because high-shear rotor-stator mixers can cause protein unfolding and aggregate formation. If subvisible particles above 10 µm are observed, the batch may fail compendial particulate matter testing under USP <787> or Ph. Eur. 2.9.19. Aggregation can also reduce enzymatic activity by burying the active-site zinc ion within inactive multimers.

The 0.22 µm sterilization filter should be integrity-tested before and after filtration by bubble point or diffusion test according to manufacturer specifications; the maximum transmembrane pressure should not exceed the filter cassette limit, typically 2.0 bar for polyethersulfone capsules. A prefilter of 0.45 µm may reduce membrane fouling when the bulk solution contains visible particulates.

For lyophilized injectable cakes, the freeze-drying cycle should maintain product temperature below the collapse temperature of the formulation, commonly between -25°C and -35°C during primary drying, with chamber pressure between 0.2 mbar and 0.4 mbar. These parameters are formulation-specific and must be derived from freeze-drying microscopy and thermal characterization. A collapsed cake is a batch failure because it can produce long reconstitution times and particulate matter in the final injection.

The thermal inactivation threshold is the controlling variable for terminal sterilization choices

Lysostaphin cannot withstand dry-heat terminal sterilization or moist-heat autoclaving at 121°C because the enzyme unfolds and loses catalytic activity. Published stability data indicate that exposure to 60°C for 1 h commonly destroys most measurable activity, so terminal sterilization options for liquid dosage forms are limited to aseptic filtration or low-dose irradiation of the dried cake. Gamma irradiation of lyophilized powder at a nominal dose of 25 kGy may be feasible, but the manufacturer must confirm retained activity and monitor radiolytic by-products in the finished product. Electron-beam irradiation is less suitable for lyophilized cakes because dose penetration and dose mapping require careful tray configuration.

For medicated feeds and premixes that may be exposed to hot pelleting, the conditioning temperature is a critical limit. Standard feed pelleting often operates at 70–85°C, which is above the inactivation threshold of lysostaphin. The API should therefore be added after pelleting via post-pellet liquid application or micro-dosing systems, or the feed should be processed as a non-pelleted meal or low-temperature extrudate. If post-pellet application is used, the liquid carrier should be non-aqueous or buffered at neutral pH and applied with a spray nozzle that limits shear and heat.

Compared with beta-lactam antibiotics that target penicillin-binding proteins, lysostaphin directly cleaves the pentaglycine cross-bridge of staphylococcal peptidoglycan. It retains activity against some methicillin-resistant Staphylococcus aureus strains because the target structure is distinct from penicillin-binding protein 2a. The enzyme has little activity against Gram-negative bacteria, which possess an outer membrane that limits access to the peptidoglycan. This narrow spectrum can reduce disruption of the normal gut microbiota when used as a veterinary antimicrobial, but susceptibility should be confirmed by species-level identification and minimum inhibitory concentration testing according to CLSI VET01 or EUCAST veterinary breakpoints where available. Published data for the specific formulation configurations described here may be limited; therefore, each veterinary manufacturer must establish formulation-specific stability, activity, and impurity data under its own quality system.